- Home
- CHW vs KMDA Comparison
CHW vs KMDA Comparison
Compare CHW & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHW
- KMDA
- Stock Information
- Founded
- CHW 2007
- KMDA 1990
- Country
- CHW United States
- KMDA Israel
- Employees
- CHW N/A
- KMDA N/A
- Industry
- CHW Investment Managers
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CHW Finance
- KMDA Health Care
- Exchange
- CHW Nasdaq
- KMDA Nasdaq
- Market Cap
- CHW 488.6M
- KMDA 392.2M
- IPO Year
- CHW N/A
- KMDA N/A
- Fundamental
- Price
- CHW N/A
- KMDA $6.84
- Analyst Decision
- CHW
- KMDA Strong Buy
- Analyst Count
- CHW 0
- KMDA 2
- Target Price
- CHW N/A
- KMDA $13.00
- AVG Volume (30 Days)
- CHW 195.2K
- KMDA 56.5K
- Earning Date
- CHW 01-01-0001
- KMDA 11-12-2025
- Dividend Yield
- CHW 9.27%
- KMDA 2.92%
- EPS Growth
- CHW N/A
- KMDA 27.97
- EPS
- CHW N/A
- KMDA 0.32
- Revenue
- CHW N/A
- KMDA $169,517,000.00
- Revenue This Year
- CHW N/A
- KMDA $14.49
- Revenue Next Year
- CHW N/A
- KMDA $10.12
- P/E Ratio
- CHW N/A
- KMDA $20.74
- Revenue Growth
- CHW N/A
- KMDA 9.67
- 52 Week Low
- CHW $5.07
- KMDA $5.18
- 52 Week High
- CHW $6.54
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- CHW 74.48
- KMDA 41.12
- Support Level
- CHW $7.47
- KMDA $6.50
- Resistance Level
- CHW $7.67
- KMDA $6.89
- Average True Range (ATR)
- CHW 0.08
- KMDA 0.13
- MACD
- CHW 0.01
- KMDA -0.01
- Stochastic Oscillator
- CHW 95.31
- KMDA 38.50
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.